Main variables;No. of employees;Total
No. of companies carrying out R&D in Biotechnology;Fewer than 250 employees;1.126
No. of companies carrying out R&D in Biotechnology;250 or more employees;108
No. of companies carrying out R&D in Biotechnology;Total 2020;1.233
%Companies according to biotechnology used: Genetic code;Fewer than 250 employees;30,9
%Companies according to biotechnology used: Genetic code;250 or more employees;40,2
%Companies according to biotechnology used: Genetic code;Total 2020;31,7
%Companies according to biotechnology used: Functional units;Fewer than 250 employees;37,4
%Companies according to biotechnology used: Functional units;250 or more employees;50,4
%Companies according to biotechnology used: Functional units;Total 2020;38,5
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Fewer than 250 employees;21,6
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;250 or more employees;34,5
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total 2020;22,8
%Companies according to biotechnology used: Bioprocesses;Fewer than 250 employees;51,7
%Companies according to biotechnology used: Bioprocesses;250 or more employees;71
%Companies according to biotechnology used: Bioprocesses;Total 2020;53,4
%Companies according to biotechnology used: Sub-cellular organisms;Fewer than 250 employees;7,8
%Companies according to biotechnology used: Sub-cellular organisms;250 or more employees;16,8
%Companies according to biotechnology used: Sub-cellular organisms;Total 2020;8,6
%Companies according to biotechnology used: Bio-computing;Fewer than 250 employees;22,2
%Companies according to biotechnology used: Bio-computing;250 or more employees;22,3
%Companies according to biotechnology used: Bio-computing;Total 2020;22,3
%Companies according to biotechnology used: Nanobiotechnology;Fewer than 250 employees;10,5
%Companies according to biotechnology used: Nanobiotechnology;250 or more employees;12,1
%Companies according to biotechnology used: Nanobiotechnology;Total 2020;10,6
%Companies according to biotechnology used: Other;Fewer than 250 employees;14,7
%Companies according to biotechnology used: Other;250 or more employees;9,3
%Companies according to biotechnology used: Other;Total 2020;14,2
Companies in which biotechnology activities are: Main and/or exclusive;Fewer than 250 employees;590
Companies in which biotechnology activities are: Main and/or exclusive;250 or more employees;25
Companies in which biotechnology activities are: Main and/or exclusive;Total 2020;615
Companies in which biotechnology activities are: A secondary line of business;Fewer than 250 employees;156
Companies in which biotechnology activities are: A secondary line of business;250 or more employees;22
Companies in which biotechnology activities are: A secondary line of business;Total 2020;178
Companies in which biotechnology activities are: A tool necessary for production;Fewer than 250 employees;379
Companies in which biotechnology activities are: A tool necessary for production;250 or more employees;61
Companies in which biotechnology activities are: A tool necessary for production;Total 2020;440
%Company by field(s) of ultimate application of biotechnology use: Human Health;Fewer than 250 employees;46,2
%Company by field(s) of ultimate application of biotechnology use: Human Health;250 or more employees;46,5
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total 2020;46,3
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Fewer than 250 employees;16,9
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;250 or more employees;9,3
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total 2020;16,2
%Company by field(s) of ultimate application of biotechnology use: Food products;Fewer than 250 employees;31,7
%Company by field(s) of ultimate application of biotechnology use: Food products;250 or more employees;35,6
%Company by field(s) of ultimate application of biotechnology use: Food products;Total 2020;32
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Fewer than 250 employees;25,6
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;250 or more employees;14,1
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total 2020;24,6
%Company by field(s) of ultimate application of biotechnology use: Environment;Fewer than 250 employees;15,3
%Company by field(s) of ultimate application of biotechnology use: Environment;250 or more employees;17,7
%Company by field(s) of ultimate application of biotechnology use: Environment;Total 2020;15,5
%Company by field(s) of ultimate application of biotechnology use: Industry;Fewer than 250 employees;13,1
%Company by field(s) of ultimate application of biotechnology use: Industry;250 or more employees;11,1
%Company by field(s) of ultimate application of biotechnology use: Industry;Total 2020;12,9
Personnel in R&D in biotechnology (no. of persons);Fewer than 250 employees;9.325
Personnel in R&D in biotechnology (no. of persons);250 or more employees;4.119
Personnel in R&D in biotechnology (no. of persons);Total 2020;13.444
Personnel in R&D in biotechnology (no. of persons): Researchers;Fewer than 250 employees;5.272
Personnel in R&D in biotechnology (no. of persons): Researchers;250 or more employees;2.106
Personnel in R&D in biotechnology (no. of persons): Researchers;Total 2020;7.378
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Fewer than 250 employees;4.053
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;250 or more employees;2.013
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;Total 2020;6.066
Personnel in R&D in biotechnology (no. of persons): women;Fewer than 250 employees;4.869
Personnel in R&D in biotechnology (no. of persons): women;250 or more employees;2.632
Personnel in R&D in biotechnology (no. of persons): women;Total 2020;7.501
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Fewer than 250 employees;2.752
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;250 or more employees;1.299
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;Total 2020;4.052
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Fewer than 250 employees;2.117
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;250 or more employees;1.333
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;Total 2020;3.450
Personnel in R&D in biotechnology (FTE);Fewer than 250 employees;6.291,5
Personnel in R&D in biotechnology (FTE);250 or more employees;3.110,4
Personnel in R&D in biotechnology (FTE);Total 2020;9.401,9
Personnel in R&D in biotechnology (FTE): Researchers;Fewer than 250 employees;3.811,8
Personnel in R&D in biotechnology (FTE): Researchers;250 or more employees;1.586,5
Personnel in R&D in biotechnology (FTE): Researchers;Total 2020;5.398,3
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Fewer than 250 employees;2.479,7
Personnel in R&D in biotechnology (FTE): Technicians and assistants;250 or more employees;1.523,9
Personnel in R&D in biotechnology (FTE): Technicians and assistants;Total 2020;4.003,6
Personnel in R&D in biotechnology (FTE): women;Fewer than 250 employees;3.385,8
Personnel in R&D in biotechnology (FTE): women;250 or more employees;2.040,5
Personnel in R&D in biotechnology (FTE): women;Total 2020;5.426,2
Personnel in R&D in biotechnology (FTE): (women) Researchers;Fewer than 250 employees;2.020,5
Personnel in R&D in biotechnology (FTE): (women) Researchers;250 or more employees;996
Personnel in R&D in biotechnology (FTE): (women) Researchers;Total 2020;3.016,4
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Fewer than 250 employees;1.365,3
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;250 or more employees;1.044,5
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;Total 2020;2.409,8
Internal expenditure on R&D (thousands of euros);Fewer than 250 employees;586.635
Internal expenditure on R&D (thousands of euros);250 or more employees;310.698
Internal expenditure on R&D (thousands of euros);Total 2020;897.333
1) By nature of the expense: Current expenses;Fewer than 250 employees;520.977
1) By nature of the expense: Current expenses;250 or more employees;296.432
1) By nature of the expense: Current expenses;Total 2020;817.409
1.1) Remuneration to researchers;Fewer than 250 employees;182.849
1.1) Remuneration to researchers;250 or more employees;112.856
1.1) Remuneration to researchers;Total 2020;295.705
1.2) Remuneration to technicians and assistants;Fewer than 250 employees;90.123
1.2) Remuneration to technicians and assistants;250 or more employees;66.730
1.2) Remuneration to technicians and assistants;Total 2020;156.853
1.3) Other current expenses;Fewer than 250 employees;248.005
1.3) Other current expenses;250 or more employees;116.847
1.3) Other current expenses;Total 2020;364.852
2) By nature of the expense: Capital expenses;Fewer than 250 employees;65.658
2) By nature of the expense: Capital expenses;250 or more employees;14.266
2) By nature of the expense: Capital expenses;Total 2020;79.924
2.1) Land and buildings;Fewer than 250 employees;6.331
2.1) Land and buildings;250 or more employees;3.941
2.1) Land and buildings;Total 2020;10.272
2.2) Equipment and instruments;Fewer than 250 employees;46.970
2.2) Equipment and instruments;250 or more employees;9.640
2.2) Equipment and instruments;Total 2020;56.609
2.3) Acquisition of specific R&D software;Fewer than 250 employees;4.475
2.3) Acquisition of specific R&D software;250 or more employees;364
2.3) Acquisition of specific R&D software;Total 2020;4.839
2.4) Otros productos de propiedad intelectual específicos para I+D;Fewer than 250 employees;7.882
2.4) Otros productos de propiedad intelectual específicos para I+D;250 or more employees;321
2.4) Otros productos de propiedad intelectual específicos para I+D;Total 2020;8.203
1.1) By origin of the funds: Own funds;Fewer than 250 employees;406.605
1.1) By origin of the funds: Own funds;250 or more employees;206.492
1.1) By origin of the funds: Own funds;Total 2020;613.097
1.2) By origin of the funds: From companies;Fewer than 250 employees;62.831
1.2) By origin of the funds: From companies;250 or more employees;23.253
1.2) By origin of the funds: From companies;Total 2020;86.085
1.3) By origin of the funds: Public Administration funds;Fewer than 250 employees;71.590
1.3) By origin of the funds: Public Administration funds;250 or more employees;20.550
1.3) By origin of the funds: Public Administration funds;Total 2020;92.140
1.4) By origin of the funds: From Universities;Fewer than 250 employees;548
1.4) By origin of the funds: From Universities;250 or more employees;306
1.4) By origin of the funds: From Universities;Total 2020;853
1.5) By origin of the funds: From non profit private institutions;Fewer than 250 employees;2.496
1.5) By origin of the funds: From non profit private institutions;250 or more employees;2.185
1.5) By origin of the funds: From non profit private institutions;Total 2020;4.682
1.6) By origin of the funds: Foreign funds;Fewer than 250 employees;42.564
1.6) By origin of the funds: Foreign funds;250 or more employees;57.912
1.6) By origin of the funds: Foreign funds;Total 2020;100.476
Purchase of R&D services in biotechnology (thousands of euros);Fewer than 250 employees;48.478
Purchase of R&D services in biotechnology (thousands of euros);250 or more employees;36.533
Purchase of R&D services in biotechnology (thousands of euros);Total 2020;85.011
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Fewer than 250 employees;23.128
Purchase of R&D services in biotechnology (thousands of euros): In Spain;250 or more employees;31.114
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total 2020;54.243
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Fewer than 250 employees;25.350
Purchase of R&D services in biotechnology (thousands of euros): Abroad;250 or more employees;5.419
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total 2020;30.768
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Fewer than 250 employees;40,9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;250 or more employees;22,4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total 2020;39,2
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Fewer than 250 employees;11,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;250 or more employees;14
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total 2020;11,7
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Fewer than 250 employees;12,9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;250 or more employees;8,4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total 2020;12,5
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Fewer than 250 employees;10,8
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;250 or more employees;11,2
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total 2020;10,9
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Fewer than 250 employees;14,7
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;250 or more employees;10,3
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total 2020;14,3
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Fewer than 250 employees;17,4
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;250 or more employees;7,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total 2020;16,5
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Fewer than 250 employees;15,2
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;250 or more employees;13,1
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total 2020;15
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Fewer than 250 employees;36
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;250 or more employees;31
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total 2020;36
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Fewer than 250 employees;47,2
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;250 or more employees;41
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total 2020;46,7
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Fewer than 250 employees;19,3
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;250 or more employees;15,9
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total 2020;19
% Companies that have requested biotechnology patents in Biotechnology;Fewer than 250 employees;17,3
% Companies that have requested biotechnology patents in Biotechnology;250 or more employees;17,7
% Companies that have requested biotechnology patents in Biotechnology;Total 2020;17,3
Number of patents requested;Fewer than 250 employees;600
Number of patents requested;250 or more employees;81
Number of patents requested;Total 2020;681
% Companies with income of an international origin related to biotechnological activities;Fewer than 250 employees;23,6
% Companies with income of an international origin related to biotechnological activities;250 or more employees;16,8
% Companies with income of an international origin related to biotechnological activities;Total 2020;23
% Turnover representing income of an international origin related to biotechnological activities;Fewer than 250 employees;5,6
% Turnover representing income of an international origin related to biotechnological activities;250 or more employees;0,9
% Turnover representing income of an international origin related to biotechnological activities;Total 2020;1,6
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Fewer than 250 employees;44,7
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;250 or more employees;69,7
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total 2020;55,9
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Fewer than 250 employees;55,3
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;250 or more employees;30,3
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total 2020;44,1
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Fewer than 250 employees;97,2
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;250 or more employees;67,6
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total 2020;83,9
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Fewer than 250 employees;1,1
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;250 or more employees;31,5
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total 2020;14,7
% Income of an international origin related with activities according to the classification: Operating source abroad;Fewer than 250 employees;0,7
% Income of an international origin related with activities according to the classification: Operating source abroad;250 or more employees;0,9
% Income of an international origin related with activities according to the classification: Operating source abroad;Total 2020;0,8
% Income of an international origin related with activities according to the classification: Other;Fewer than 250 employees;1,1
% Income of an international origin related with activities according to the classification: Other;250 or more employees;0
% Income of an international origin related with activities according to the classification: Other;Total 2020;0,6